Navigation Links
New Investors Fund Expansion of Cavidi AB
Date:11/16/2007

Funding to Lead to Improved HIV Management in Developing World

UPPSALA, Sweden, November 16 /PRNewswire/ -- Cavidi AB announced today that it has signed an agreement with a consortium of American and Swedish investors. The consortium has provided over US$1.0 million of operational funding, and has committed to raising additional funding as necessary. The capital will be used to drive forward Cavidi's newly adopted three-year business plan. Cavidi is the producer of ExaVir(TM) Load, an HIV viral load assay suited for resource-limited settings.

Viral load monitoring is essential for the proper management of HIV-infected patients being treated with antiretroviral drugs (ARVs). The test helps doctors use ARVs more effectively, extending a patient's length and quality of life, limiting the development of viral resistance and minimizing waste of medication.

The key members of the investment consortium include several American investors experienced in venture capital markets as well as senior Cavidi management. The three-year plan they are funding seeks to generate more than a five-fold growth in revenue. It will capitalize on the recent release of Cavidi's ExaVir Load Version 3 - a new and improved version of their HIV viral load assay. It is also part of the plan to appoint additional distributors in Asia. Further investment will be required in both working capital and equipment in order to undertake a major expansion in production capacity.

The consortium will appoint a new member to Cavidi's Board of Directors. They have also committed to raising additional capital over the life of the three-year plan as needed.

"This is an important step forward for Cavidi," said Martyn Eales, the company's CEO. "It gives us additional resources to fully promote the new version of ExaVir Load." Cavidi is also on the verge of finalizing agreements with major international non-government organizations, as well as new distributors in Africa and Asia. This will ensure their ability to capitalize on the the growing acceptance of leading HIV clinicians worldwide of viral load monitoring as an essential part of effective HIV management. "The easy-to-use, affordable and accurate HIV viral load monitoring that ExaVir Load provides is especially needed in resource-limited environments," said Eales. "It permits the optimal use of what is invariably a limited supply of ARVs."

He went on to say Cavidi expects a rapid increase in sales of ExaVir Load assay kits due to these new testing strategies as they incorporate viral load monitoring as an essential part of HIV management wherever it is provided.

About Cavidi AB

Cavidi's mission is to make medical diagnostics more accessible in those parts of the orld where resources and infrastructure are limited. Their products include ExaVir Load which is used to quantify the amount of HIV in a patient's blood, and ExaVir Drug which measures a patient's resistance to ARVs. Cavidi was founded by leading virologists at Uppsala University in Sweden in 1984.

http://www.cavidi.com


'/>"/>
SOURCE Cavidi AB
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Sector Focus Conference
2. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
3. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
4. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
5. LehmanMillet Continues Expansion with Strategic Hires
6. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
7. AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill
8. Illinois AARP Presses for Expansion of Childrens Health Insurance Program (SCHIP)
9. Expansion and Growth Spur INSPIRIS Executive Leadership Promotions
10. Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries
11. Chemizon Announces Research Collaboration Expansion With Takeda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: